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The transcriptional co-activator PGC-1 regulates functional
plasticity in adipose tissue by linking sympathetic input to the
transcriptional program of adaptive thermogenesis. We report
here a novel truncated formof PGC-1 (NT-PGC-1) produced
by alternative 3 splicing that introduces an in-frame stop codon
into PGC-1 mRNA. The expressed protein includes the first
267 amino acids of PGC-1 and 3 additional amino acids from
the splicing insert. NT-PGC-1 contains the transactivation
and nuclear receptor interaction domains but is missing key
domains involved in nuclear localization, interactionwith other
transcription factors, and protein degradation. Expression and
subcellular localization of NT-PGC-1 are dynamically regu-
lated in the context of physiological signals that regulate full-
length PGC-1, but the truncated domain structure conveys
unique properties with respect to protein-protein interactions,
protein stability, and recruitment to target gene promoters.
Therefore, NT-PGC-1 is a co-expressed, previously unrecog-
nized form of PGC-1 with functions that are both unique from
and complementary to PGC-1.
PGC-1 was identified as a brown adipocyte-enriched, cold-
inducible, and transcriptional co-activator of the nuclear recep-
tor PPAR3 (1). PGC-1 function is central to transcriptional
programs that underlie not only brown adipocyte differentia-
tion (1, 2) but also fiber-type switching in muscle (3), glucone-
ogenesis in liver (4–7), fatty acid oxidation in heart (8, 9), and
protection from oxidative stress in the central nervous system
(10). Although the physiological responses affected by PGC-1
differ among tissues, mitochondrial biogenesis and increased
cellular respiratory capacity are common elements of the tran-
scriptional program in all sites. In some tissues, PGC-1 func-
tions as a nutrient sensor, and in others its activity is regulated
by endocrine, environmental, or circadian signals (6, 11–14). In
(brown) adipose tissue, PGC-1 is a key factor in sympathetic
nervous system-induced functional plasticity, responding to
increased cAMP and translating sympathetic nervous system
input into transcriptional programs that remodel the mito-
chondrial proteome, increase oxidative capacity, and enable
thermogenesis (1, 2, 15, 16).
PGC-1 has a complex structure withmultiple domains that
act in concert to define the biological and physiological prop-
erties of the full-length protein (1, 9, 17–20). Distinct surfaces
on the PGC-1 protein enable the co-activation of a diverse
array of nuclear receptors (NRs) and transcription factors.
N-terminal leucine-rich domains (L2 and L3) mediate interac-
tions with the ligand binding domain of NRs, whereas central
and C-terminal domains mediate interactions with PPAR,
NRF1, host cell factor, MEF2C, and FOXO1. Interaction with
transcription factors directs PGC-1 to the regulatory region of
target genes and facilitates recruitment of other co-regulators,
such as SRC-1 and CREB-binding protein (via an N-terminal
transactivation domain) and the Mediator complex (via C-ter-
minal domains) (17, 21, 22). In any given cellular environment,
productive interactions between PGC-1 and downstream
effectors are subject to signaling inputs that regulate PGC-1
expression and activity through extensive post-translational
modification of the protein. Nutrient-sensing systems regulate
hepatic gluconeogenesis in part by regulating acetylation of
PGC-1 (11), which increases activation of gluconeogenic
genes viaHNF4 (5) and FOXO1 (6). Phosphorylation of specific
sites by p38 MAPK (13), AMP kinase (12), AKT (23), and
GSK-3 (14) regulate the transcriptional activity and/or pro-
tein levels of PGC-1. Transcriptional activity of PGC-1 is
also regulated by methylation of arginine residues by PRMT1
(24), and C-terminal domains regulate PGC-1 protein stabil-
ity (25). Thus, the versatility of PGC-1 as a transcriptional
co-activator in multiple contexts derives from a complex
domain structure that enables the following: first, interactions
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with multiple transcriptional factors via several distinct pro-
tein-protein interaction domains, and second, post-transla-
tional modifications (affecting activity and protein levels) by
diverse regulators and signaling inputs.
Alternative splicing of multiexon genes is common and
particularly relevant to multidomain proteins where splicing
events produce protein isoforms with unique properties
(26). The splice variant of PGC-1 identified herein (N-trun-
cated PGC-1) retains the N-terminal transcriptional acti-
vation and NR-interacting domains but is missing all domains
within aa 268–797 of the full-length protein. Thus, the distinct
properties of NT-PGC-1 are defined not only by the subset of
domains retained from the parent protein but also by the miss-
ing domains that are downstream of the splice site. Using a
combination of approaches, we show that NT-PGC-1 expres-
sion, subcellular localization, nuclear receptor interaction, and
target gene activation are dynamically regulatedwithin the con-
text of the physiological signals that regulate full-length PGC-
1. Collectively, these data support the concept that NT-
PGC-1 is an important, previously unrecognized component
of the transcriptional network that links signaling input to
PGC-1-dependent transcriptional responses.
EXPERIMENTAL PROCEDURES
Animals and Tissues—Six-week-old male C57BL/6J mice
or 3-month-old Fisher F344 rats were individually housed
and exposed to cold (4 °C) or room temperature (22–23 °C)
for 5 h prior to sacrifice using CO2 and cervical dislocation.
Tissues from PGC-1 null mice (15) were a kind gift from
Bruce Spiegelman. Human tissue (heart) harvested at
autopsy was obtained from National Disease Research Inter-
change (Philadelphia).
RNA and Protein Analysis—Total RNA was isolated from
tissues or cultured brown adipocytes using TRIzol reagent
(Invitrogen) and reverse-transcribed using oligo(dT) primers
andMoloneymurine leukemia virus reverse transcriptase (Pro-
mega). Twenty ng of cDNA was used as template for quantita-
tive reverse transcription-PCR on a Smart Cycler (Cepheid)
using cyclophilin as internal control. The primers for mouse
and rat Pgc-1 and NT-Pgc-1 mRNA (S1) used a common
forward primer and a reverse primer that spanned the junction
of exons 6 and 7 for Pgc-1 or a reverse primer that spanned the
beginning of exon 7 and the intronic sequence retained in NT-
Pgc-1 mRNA. The specificity of the respective primer sets for
Pgc-1 and NT-Pgc-1 was confirmed by sequencing cDNA
fragments amplified by each primer set from a BAT cDNA
library. The respective cDNA fragments were carefully quanti-
tated and used to prepare standards by serial 10-fold dilution of
each purified fragment. The slopes of the resulting standard
curves relating log mass of Pgc-1 and NT-Pgc-1 cDNA to
cycle threshold were 3.3 (S2). In addition, serial dilution of
BAT cDNA samples produced changes in cycle threshold that
paralleled the standard curves. The following primers were
used: mouse Ucp1 F, 5 GAT CCA AGG TGA AGG CCA GG
3, andUcp1 R, 5 GTT GAC AAG CTT TCT GTGGTGG 3;
cyclophilin F, 5-CCA TCG TGT CAT CAA GGA CTT
CAT-3 and cyclophilin R, 5-CTTGCCATCCAGCCAGGA
GGT CTT-3.
Formeasurement of protein expression, tissueswere homog-
enized under liquid nitrogen and lysed in RIPA buffer contain-
ing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40,
0.25% sodium deoxycholate, 1 mM EDTA, and protease inhibi-
tor mixture. Brown adipocytes were washed with phosphate-
buffered saline prior to lysing in the same buffer. UCP1 was
detected using our previously described polyclonal antibody
(27). For detection of PGC-1 or NT-PGC-1, lysates (100 g)
were analyzed by immunoblotting using a rabbit polyclonal
antibody raised against a GST fusion of PGC-1 (1–200 aa) or a
monoclonal antibody raised against a GST fusion of PGC-1
(1–120 aa). Both antibodieswere epitope-mappedusing a series
of overlapping 15-aa-long peptides corresponding to aa 1–200
of mouse PGC-1 (JPT Peptide Technologies). The 15-mer
peptides were spotted onto glass slides and hybridized with
each antibody to identify the specific sequences recognized by
each antibody. Immunoblots were hybridized with antibodies
raised against -actin as a loading control (Santa Cruz Biotech-
nology). Finally, the immunoreactive proteins in each blot were
visualized using species-specific second antibodies and ECL
reagent (Amersham Biosciences).
Generation and Culture of Brown Adipocyte Cell Lines—In-
terscapular brown adipose tissue was isolated from newborn
FVB mice by collagenase digestion and immortalized by trans-
fectionwith the retroviral pBabe vector expressing SV40T anti-
gen as described previously (28, 29). After a 14-day selection
using 1 g/ml puromycin, the immortalized preadipocytes
were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 20% fetal bovine serum and antibiotics. Subse-
quently, the cells were stably transformed with empty lentiviral
vector or lentiviral constructs expressing NT-PGC-1-HA or
PGC-1-V5. Following a 12-day selection with blasticidin (7.5
g/ml), 4–5 lines from each group were selected, and expres-
sion of NT-PGC-1-HA or PGC-1-V5 was confirmed by
Western blotting. The respective cell lines were maintained
in growth medium containing Dulbecco’s modified Eagle’s
medium supplemented with 20% fetal bovine serum and anti-
biotics. At 80% confluence, culture medium was supplemented
with 20 nM insulin, 1 nM triiodothyronine, 0.5 mM isobutyl-
methylxanthine, 2 g/ml dexamethasone, and 250 M indo-
methacin for 48 h to induce differentiation. Thereafter, cells
were maintained in differentiation medium (Dulbecco’s modi-
fied Eagle’s medium supplemented with 20% fetal bovine
serum, antibiotics, 20 nM insulin, and 1 nM triiodothyronine)
until full differentiation was achieved on day 7.
To examine induction of NT-PGC-1 by cAMP, differenti-
ated brown adipocytes were treated with 100M 8-CPT-cAMP
for 14 h. Induction of the thermogenic gene program by NT-
PGC-1 was examined by treating differentiated brown adipo-
cyte cell lines expressing NT-PGC-1-HA, PGC-1-V5, or
empty vector with a ligand mixture containing 100 M 8-CPT-
cAMP, 10 M WY14693, or BRL49653, and 5 M 9-cis-RA.
Immunocytochemistry and Cell Volume Measurements—
CHO-K1 cells, brown preadipocytes stably transformed with
NT-PGC-1-HA, or fully differentiated, stably transformed
brown adipocytes were seeded at a density of 30,000 cells per
well and grown overnight on polylysine-coated coverslips.
CHO-K1 cells were transiently transfected with NT-PGC-
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1-HA in pcDNA3.1 using FuGENE (Roche Applied Science).
After 12 h, serum-deprived CHO-K1 cells or the stably trans-
formed preadipocytes and adipocytes were treated as described
in each figure legend, washedwith prewarmed phosphate-buff-
ered saline, and fixed using 4% paraformaldehyde. The fixed
cells were permeabilized with 0.5% Triton X-100 and sequen-
tially incubated with rabbit anti-HA antibody (Abcam), goat
anti-rabbit second antibody coupled to fluorescein isothio-
cyanate (Invitrogen), and DAPI. Following stringent washes
with 0.5% Triton X-100 and 0.1% Tween 20, coverslips were
mounted with Vectashield (Vector Laboratories). Subcellu-
lar localization of NT-PGC-1 and DAPI was determined by
confocal microscopy using a Zeiss LSM 510 Meta, and the
image stacks were analyzed using ImageJ software. Treatment-
dependent changes in nuclear NT-PGC-1 content were
assessed by expressing NT-PGC-1 signal intensity co-local-
ized with DAPI as a percentage of NT-PGC-1 signal intensity
measured in the whole cell. In addition, the relative concentra-
tions of NT-PGC-1 in the nucleus and cytosol were deter-
mined independently by measuring nuclear and cytosolic vol-
ume in cells stainedwithDAPI andCellTrackerGreenCMFDA
(Invitrogen). The cells were imaged using confocal microscopy
and analyzed using Imaris software (Bitplane). Nuclear and
cytoplasmicNT-PGC-1 concentrationswere calculated as the
ratio of NT-PGC-1 signal intensity in the nucleus to nuclear
area andNT-PGC-1 signal intensity in the cytosol to cytosolic
area. Treatment-dependent changes in subcellular localization
of NT-PGC-1were assessed using the ratio of nuclear to cyto-
solic NT-PGC-1 concentration, with ratios approaching 1
indicative of equilibration of NT-PGC-1 across the nuclear
membrane and ratios 1 or 1 indicative of cytosolic or
nuclear sequestration of NT-PGC-1, respectively.
Interaction of NT-PGC-1 with Nuclear Receptors—To
examine interaction ofNT-PGC-1withPPARs,CHO-K1 cells
were transiently transfected with GAL4-responsive luciferase
reporter gene (pGK), plasmids expressing the GAL4 DNA
binding domain fused to either full-length PPAR or PPAR,
pcDNA3.1 plasmids expressing either mouse PGC-1 or NT-
PGC-1, and a pRL-SV40 control plasmid expressing Renilla
luciferase for normalization. After 24 h, the cells were treated
with vehicle (DMSO), 10 M WY14693 (Sigma), or 10 M
BRL49653 (Cayman Chemicals) for 24 h. Cells were harvested
in lysis buffer (Promega) formeasurement of luciferase activity.
For in vitro binding assays, GST-PGC-1 or GST-NT-PGC-1
were expressed in bacteria (BL21) by -1-thio-D-galactopy-
ranoside induction for 3 h at 30 °C and purified on Sepharose
beads containing glutathione. 35S-Labeled PPAR and
PPAR were produced in the TNT reticulocyte lysate system
(Promega) and incubated for 1 h with equal amounts of the in
vitro translated proteins in binding buffer (20 mM Hepes, 75
mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, 0.05% Nonidet P-40,
2 mM dithiothreitol, and 10% glycerol (pH 7.7)). After pull-
down and washing of each fusion protein bound to glutathi-
one-agarose beads, bound proteins were separated by SDS-
PAGE, and autoradiographs were analyzed by scanning
densitometry (Bio-Rad).
Co-immunoprecipitation of NT-PGC-1 with PPAR—
Whole cell extracts from COS cells expressing PPAR-FLAG
and NT-PGC-1-HA were pre-cleared with protein G and
incubated with either anti-HA, rabbit preimmune IgG (Santa
CruzBiotechnology), and either anti-FLAG (Sigma; FLAG-M2)
or mouse preimmune IgG (Santa Cruz Biotechnology) at 4 °C.
After incubation with protein G, the supernatants were used to
evaluate immunoprecipitation efficiency, although the remain-
ing pellets were probedwith anti-FLAG or anti-HA antibody to
measure protein-protein interaction, followed by re-probing
with either anti-HA or anti-FLAG to evaluate the immunopre-
cipitation efficiency.
Recruitment of NT-PGC-1 to Target Gene Promoters—
Chromatin immunoprecipitation assays were used to examine
protein-DNA interaction of NT-PGC-1 with the Ucp1 or
Cpt-1promoters in brown adipocytes stably transformedwith
NT-PGC-1-HA (30, 31). In brief, 4 ODs of the cross-linked,
pre-cleared chromatin was immunoprecipitated with rabbit
anti-HA antibody or anti-rabbit IgG (Santa Cruz Biotechnol-
ogy). Real time PCR was used to quantify protein-DNA inter-
action of NT-PGC-1 with theUcp1 orCpt-1 promoters, and
specificity of the PCRs was confirmed by agarose gel electro-
phoresis. The respective primers were as follows: Ucp1 pro-
moter F, 5-GAG AAG AAC ACG GAC ACT AGG, and Ucp1
promoter primer R, 5-GAG AGA GCA GTA GGG GTG AG;
Cpt-1 promoter F, 5-ACCTTGAGCCCTGGAATTAGG-
3, andCpt-1 promoter R, 5-ACCAGAACACCCTCCTTT
TGG-3. Intragenic regions 3 of the respective Cpt-1 and
Ucp1 promoters were amplified as negative controls with the
following primers: Cpt-1 gene F, 5-GTC CTT GAC TCT
CTT GTG GAC ACC, and Cpt-1 gene R, 5-GGT CAT AGG
GTATGCTTTGGACACT;Ucp1 gene F, 5-CTTGCATTA
AGG CAG TTG CCC ACT G and Ucp1 gene R, 5-GGA TGT
CTA TTT AAT AGC AGC TTG GTC.
Assessment of Mitochondrial Biogenesis—Changes in mito-
chondrial DNA copy number were assessed by measuring the
ratio of mitochondria to nuclear DNA (32) in differentiated
brown adipocytes stably transformed with empty vector,
NT-PGC-1-HA or PGC-1-V5. In companion experiments,
mitochondrial mass was measured using fluorescence micros-
copy with TRITC filters (excitation 484/15 and emission 555/
25) in differentiated brown adipocytes prestained with Mito-
fluor Red 589 (Invitrogen).
RESULTS
Alternative 3-Splicing of Pgc-1 Gene Produces Truncated
Form of PGC-1—In the process of cloning full-length Pgc-1
from a mouse BAT cDNA library, we identified cDNA clones
that contained an extra 31 nucleotides between nucleotides 891
and 892 of the published sequence. The insert corresponded to
31 bp at the 3 end of the sixth Pgc-1 intron, which is normally
spliced out during gene transcription (Fig. 1A). Examination of
the intronic sequence revealed two consensus 3 splice acceptor
sites in intron 6 as follows: an upstream site that leads to the
31-bp inclusion we identified, and a downstream site that leads
to the known, reported Pgc-1 mRNA isoform. Splicing at the
upstream acceptor site is noteworthy because it introduces an
in-frame stop codon (Fig. 1A). Translation of the alternatively
spliced mRNA with the 31-bp insert is predicted to produce a
truncated form of PGC-1 containing the first 267 aa of
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PGC-1 and 3 additional aa from
the first three codons of the insert
before the stop codon. We denote
the truncated form of PGC-1 as
N-truncated PGC-1 (NT-PGC-
1). Examination of the NCBI nu-
cleotide data base shows a variant
form of human Pgc-1 mRNA (ac-
cession number AB061325) that
uses the same alternative splicing
site we have detected for mouse
Pgc-1 mRNA (accession number
AB061324). In addition, alignment
of the genomic DNA sequences
from the end of exon 6 to the begin-
ning of exon 7 for mouse, rat,
human, chimp, cow, dog, horse, and
cat Pgc-1 reveals that the sequence
spanning the 3 splice sites for NT-
Pgc-1 and Pgc-1 identified in the
mouse sequence are completely
conserved across all of these species
(Fig. 1B).
Examination of the predicted
NT-PGC-1 protein indicates re-
tention of two essential PGC-1
domains as follows: the N-ter-
minal domain (Fig. 1C) that re-
cruits SRC-1 and CREB-binding
protein and carries the transcrip-
tional activation function, and the
twoLXXLL-like (L2–L3)motifs that
mediate interactions with NRs. NT-
PGC-1 also retains twoof the three
described p38 MAPK phosphoryla-
tion sites (13). NT-PGC-1 lacks
the nuclear localization sequences
of the parent protein, the ligand-
independent PPAR binding
region (aa 338–403), the SR-rich
and RRM domains, the FOXO1,
MEFC2, and TRAP220 interaction
domains (6, 33), and multiple sites
of post-translation modification
and regulation (e.g. the GSK-3,
AMP kinase, and AKT phosphor-
ylation sites (12–14, 23), the argi-
nine methylation sites (24), multi-
ple lysine acetylation sites (11, 34),
and the C-terminal domains
involved in regulating protein sta-
bility (25)). Thus, the truncated
domain structure of NT-PGC-1
infers that it would possess unique
properties encompassing func-
tions that are both complementary
to and unique from full-length
PGC-1 (Fig. 1C).
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In Vivo and in Vitro Regulation of NT-PGC-1 and PGC-1
Expression—A biological role for NT-PGC-1 is predicated on
it being expressed. To evaluate NT-Pgc-1 expression in a rel-
evant physiological context, we determined the levels of NT-
Pgc-1 and Pgc-1 mRNA (using isoform-specific primers, see
supplemental Fig. S1 and Fig. S2 for details) and protein in the
BAT of C57BL/6Jmice kept at room temperature or exposed to
cold (4 °C) for 5 h. At the mRNA level, NT-Pgc-1 and Pgc-1
were expressed at a ratio of 1 to 1.75 in BAT from control mice
retained at room temperature (23 °C) (Fig. 2A). Cold exposure
induced both mRNA species dramatically, by 16.3-fold (NT-
Pgc-1) and 14.7-fold (Pgc-1), resulting in comparable expres-
sion of the two isoforms (Fig. 2A). At the protein level, NT-
PGC-1 was weakly detected at 35 kDa in BAT whole cell
extracts frommice at room temperature, whereas PGC-1 was
essentially undetectable under these conditions (Fig. 2A).
Cold exposure produced a significant increase in the expres-
sion of both isoforms (Fig. 2A). Thus, in BAT, NT-Pgc-1
mRNA is an abundant message that is present at levels com-
parable with those of Pgc-1 mRNA, is increased by expo-
sure to cold, and leads to expression of a truncated PGC-1
protein of the expected size.
Exposure to cold leads to -adrenergic stimulation and
increased cAMP in BAT. To examine whether NT-PGC-1
expression was regulated by cAMP in an in vitro model of
adaptive thermogenesis, differentiated brown adipocytes
were treated with vehicle or the cell-permeable cAMP ana-
log 8-CPT-cAMP for 12 h. As observed in BAT from mice at
room temperature, basal expression of both proteins was low to
undetectable (Fig. 2B). The cAMP analog mimicked the effect
of cold exposure in BAT and produced a significant increase in
expression of both proteins in the cells (Fig. 2B). These results
complement our in vivo findings and illustrate that NT-
PGC-1 expression is similarly regulated in bothmodels by the
physiological signals that regulate full-length PGC-1.
In liver, PGC-1 is known to be induced upon fasting (4, 7).
Hepatic PGC-1 andNT-PGC-1mRNA levels were similar in
fed mice and induced by fasting by 10-fold (Fig. 2C). As in
BAT, transcriptional activation of the hepatic PGC-1 gene by
fasting did not alter the splicing ratio of the respective isoforms.
NT-PGC-1 protein was faintly detected as a doublet around
35 kDa in hepatic nuclear extracts from fed mice, whereas
full-length PGC-1 was essentially undetectable under these
conditions (Fig. 2C). Fasting induced a significant increase in
expression of both protein isoforms, proportional to the
increase in mRNA of each isoform under these conditions
(Fig. 2C).
To assess whether NT-PGC-1 is expressed in other tissues
where PGC-1 function is important,NT-Pgc-1 mRNA levels
were also examined in brain and kidney (Fig. 2D), as well as
skeletal muscle, white adipose tissue, spleen, and heart. Brain
was unique among the tissues studied in having the highest
ratio of NT-Pgc-1 to Pgc-1 mRNA, whereas NT-Pgc-1 and
Pgc-1mRNA levels were comparable in skeletal muscle, white
adipose tissue, spleen, and heart (data not shown). Thus, alter-
native splicing of Pgc-1 does not appear to favor formation of
either transcript, except in brain where NT-Pgc-1 mRNA
appears to be slightly favored. To confirm that the 35-kDa pro-
tein we detect with our PGC-1 antibody is indeed derived
from the Pgc-1-encoding gene, we probed tissue lysates from
control and PGC-1 null mice (15). NT-PGC-1 was specifi-
cally detected at 35–38 kDa in BAT, brain, and kidney in
control but not PGC-1 null mice (Fig. 2E). NT-PGC-1 pro-
tein expressionwas highest in brain and lowest in liver, whereas
expression in BAT and kidney was comparable and intermedi-
ate to liver and brain (Fig. 2E). It is currently unclear why NT-
PGC-1 migrates at slightly different sizes among the tissues.
Given the potential for post-translational modification and the
existence of alternative promoters and first exons (35), it seems
likely that tissue-specific modifications and/or promoter usage
contribute to differential mobility (Fig. 2E). Finally, the rank
order of mRNA (Fig. 2D) and protein expression (Fig. 2E) was
roughly comparable among tissues.
As noted in Fig. 1B, the highly conserved sequence around
the alternative 3 splice sites of PGC-1 suggests that
NT-PGC-1 should be readily detected in tissues from these
species. To test this hypothesis, total RNA and whole cell
lysates from BAT of rats exposed to cold (4 °C) or room tem-
perature for 5 hwere examined, alongwith rat brain andhuman
brain and heart. In rat BAT, neither PGC-1 isoform was
detectable at room temperature by Western blot (Fig. 2F),
whereas cold exposure produced a robust increase in expres-
sion of both isoforms. The fold increase is difficult to estimate,
even when 3-fold more BAT whole cell extract is loaded from
room temperature versus cold-exposed rats (Fig. 2F). However,
the relative expression of both isoforms appears comparable at
the 5-h time point (Fig. 2F), and as noted previously, the NT-
PGC-1 isoform is expressed as a doublet in this tissue. In con-
trast, NT-PGC-1 is expressed as a single, more slowly migrat-
ing protein in whole cell lysates from rat brain (Fig. 2G). In
addition, full-length PGC-1 is faintly detected in these
extracts (Fig. 2G). NT-PGC-1 protein is also readily detected
in whole cell extracts of human heart collected 3–4 h post-
mortem (Fig. 2H). Full-length PGC-1 is not evident in this
Western blot (Fig. 2H), although isolation of nuclei and probing
of nuclear extracts revealed expression of PGC-1 (data not
shown). Messenger RNA for both protein isoforms was readily
detected in our human heart sample and in both tissues from
rat (data not shown). Together, these findings strongly support
the conclusion that NT-PGC-1 is co-expressed with PGC-1
in human, rat, and probably many other species.
We noted that althoughNT-Pgc-1 and Pgc-1mRNA levels
were similar in most tissues, NT-PGC-1 protein was detected
at higher levels than full-length PGC-1 (e.g. Fig. 2, A–C).
Although we cannot exclude that differences in the physical
properties of the two isoforms (e.g. higher solubility in the
FIGURE 1. Schematic diagrams of alternative splicing, sequence alignments, and domain structure of PGC-1. A, schematic diagram showing alternative
splicing of the Pgc-1 gene. B, alignment of genomic sequence of Pgc-1 from end of exon 6 to beginning of exon 7 for mouse, rat, human, chimp, cow, dog,
horse, and cat. C, diagram of domain structure of PGC-1 and NT-PGC-1. NLS, nuclear localization sequence; RS, arginine-serine-rich domain; ERR, estrogen-
related receptor; RRM, RNA recognition motif.
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extraction buffer or more efficient
transfer ofNT-PGC-1 from the gel
to the membrane) contribute to the
differences in detected levels, we
considered that the two isoforms
could have different turnover rates.
We thus assessed the relative target-
ing of PGC-1 and NT-PGC-1 to
the proteosome. Following tran-
sient transfection of CHO-K1 cells
with similar PGC-1 and NT-
PGC-1 expression vectors, the
respective protein levels were deter-
mined after treating the cells with
vehicle or the proteosome inhibitor
MG132 for 5 h. In vehicle-treated
conditions, NT-PGC-1 expression
was 5-fold higher than PGC-1
(Fig. 2I).However, the proteinswere
expressed at comparable levels after
inhibition of the proteosome, the
result of a 10.6-fold increase in
PGC-1 expression but only a 1.8-
fold increase in NT-PGC-1 (Fig.
2I). The results support the view
that NT-PGC-1 is degraded less
quickly by the proteosome than the
relatively short lived PGC-1.
Post-translational Regulation of
Subcellular Localization of NT-PGC-
1—Although NT-PGC-1 lacks
the nuclear localization sequences
of full-length PGC-1, the size of
the translated protein should not
impede it moving through nuclear
pores and equilibrating across the
nuclear membrane (36). To confirm
the presence of NT-PGC-1 in the
nucleus and to assess the effects of
signaling inputs on its cellular dis-
tribution, we measured nuclear and
cytoplasmic content of HA-tagged
NT-PGC-1 in Chinese hamster
ovary cells using confocal micros-
copy. Analysis of confocal image
stacks from cells under basal condi-
tions indicated that 10% of the
total cell NT-PGC-1-HA signal
co-localized with DAPI (Fig. 3A).
Stated another way, 90% of the
cellular content of NT-PGC-1-HA
was found in the cytosol under these
conditions (Fig. 3A). To examine
whether signaling inputs known to
regulate PGC-1 under physiologi-
cal conditions affected subcellular
distribution of NT-PGC-1, cells
were treated with 8-CPT-cAMP for
mRNA Splicing Produces an Active Short Isoform of PGC-1
32818 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 47 • NOVEMBER 20, 2009
1 h in the absence and presence of PKA (H89) and p38 MAPK
(SB203580) inhibitors. Activation of PKA increased nuclear
content of NT-PGC-1 from 11.1  0.4% (n  58) to 19.2 
0.6% (n  58) (Fig. 3, A, B, and E). Forskolin, which increases
cAMP by directly activating adenylyl cyclase, produced a simi-
lar enrichment in nuclear content of NT-PGC-1 (data not
shown). Inhibition of PKAwith H89 blocked the 8-CPT-cAMP
response (Fig. 3, C and E) and even reduced nuclear content of
NT-PGC-1 to below basal levels (11.1  0.4%) to 8.6  0.3%
(Fig. 3, C and E), suggesting that basal PKA activity provides
input to subcellular distribution of NT-PGC-1. The PKA-de-
pendent increase in nuclear content of NT-PGC-1 was also
decreased by 38% when p38 MAPK was inhibited by
SB203580 (Fig. 3,D and E). Collectively, these results show that
PKA regulates nuclear content of NT-PGC-1 through both
p38 MAPK-dependent and -independent mechanisms.
To assess whether the observed fraction of NT-PGC-1 in
the nucleus could be the result of NT-PGC-1 equilibrating
across the nuclear membrane, we next used a cell-specific
probe in conjunction with DAPI to measure cytoplasmic and
nuclear volumes in confocal image stacks of Chinese ham-
ster ovary cells under basal and PKA-stimulated conditions.
Nuclear volume included 14.7  0.9% of total cell volume
under basal conditions and 18.6  0.7% of total cell volume
in 8-CPT-cAMP-treated cells. These measures, used in con-
junction with measures of total NT-PGC-1 signal intensity
in the cytosol and in the nucleus, allowed us to calculate the
ratio of nuclear to cytoplasmic NT-PGC-1 concentration.
Under basal conditions, the ratio of nuclear to cytoplasmicNT-
PGC-1 was 0.680  0.003, indicating a higher concentration
of NT-PGC-1 in the cytosol versus the nucleus. Upon activa-
tion of PKA with 8-CPT-cAMP, the ratio increased to 1.200 
009, indicating accumulation of NT-PGC-1 in the nucleus
slightly beyond equilibration across the nuclear membrane.
Collectively, these findings suggest a system of regulated access
of NT-PGC-1 to the nucleus under signaling conditions that
favor its participation in transcriptional activation. It will be
important in future studies to establish how NT-PGC-1 is
being excluded from the nucleus under basal conditions and
how signaling inputs from PKA and p38 MAPK regulate this
process.
To examine subcellular distribution of NT-PGC-1 in a bio-
logically relevant cell context, studies were conducted in
immortalized brown adipocytes stably transformed with HA-
tagged NT-PGC-1. Although NT-PGC-1 is an endogenous
protein in our brown adipocyte cell line, the induction of its
expression by PKA (Fig. 2B) has the potential to confound
measurement of changes in subcellular localization under these
conditions. The strategy of measuring subcellular localization
of epitope-tagged NT-PGC-1 in this cell line avoids these
caveats and provides the added benefit of examining the issue in
cells before and after differentiation. In undifferentiated prea-
dipocytes (Fig. 4A), 10.0  0.3% of total cellular NT-PGC-1
was found in the nucleus under basal conditions (Fig. 4, A and
E), and treatmentwith 8-CPT-cAMP increasednuclear content
to 27.7  0.7% (Fig. 4, B and E). In differentiated brown adipo-
cytes, a similar 10.7 0.3%of cellularNT-PGC-1was found in
the nucleus under basal conditions (Fig. 4C), and activation of
PKA with 8-CPT-cAMP increased nuclear content to 18.7 
0.6% (Fig. 4, D and E). Together, these data indicate that NT-
PGC-1 is primarily cytosolic under basal conditions, but in
both preadipocytes and adipocytes PKA activation significantly
increases the nuclear content of the protein.
Transactivation andPhysical Interaction ofNT-PGC-1with
PPARs—NT-PGC-1 retains important functional domains,
including the leucine-rich motifs that mediate interactions
with nuclear receptors (9, 17, 20). It is of particular interest
that the domain at aa 338–403 of PGC-1 reported to confer
ligand-independent interaction with PPAR (1) would be
absent from NT-PGC-1. We used three distinct but com-
plementary approaches to assess the ligand dependence of
the interaction of NT-PGC-1 with PPAR and PPAR. In
the first approach, interaction of NT-PGC-1 or PGC-1 with
PPAR or PPAR fused to Gal4 was measured using the Gal4-
responsive luciferase reporter pGK-1. Expressed relative to
pGK1 activation by PPAR-Gal4 or PPAR-Gal4 alone, trans-
activation of PPAR-Gal4 by NT-PGC-1 (40  4-fold) was
2-fold lower than activation with PGC-1 (102  2-fold) in
the absence of ligand (Fig. 5A). Addition of ligand increased
PPAR-Gal4 activity to the same maximal level with NT-
PGC-1 and PGC-1 (Fig. 5A), although the fold increase with
NT-PGC-1 (8.4-fold) was significantly larger than PGC-1
(3-fold). In the absence of ligand, transactivation of PPAR-
Gal4 by PGC-1 (308  38-fold) was also significantly greater
than byNT-PGC-1 (40 4). Addition of ligand produced only
a modest 1.9-fold increase in PPAR-Gal4 activity in the pres-
ence of PGC-1, consistent with a significant ligand-indepen-
dent activation of PPAR by PGC-1 (1). In contrast, transac-
tivation of PPAR-Gal4 by NT-PGC-1, which was low in the
absence of ligand, was increased 8.4-fold by addition of ligand
FIGURE 2. Tissue distribution and regulation of expression of NT-PGC-1 and PGC-1. A, induction of Pgc-1 and NT-Pgc-1 mRNA and protein in brown
adipose tissue by cold exposure (4 °C) for 5 h in C57BL/6J mice. -Actin was blotted as a loading control, and data (mean  S.E.) are representative of three
experiments. Room Temp, room temperature. B, induction of PGC-1 and NT-PGC-1 protein expression in immortalized brown adipocytes from mice 12 h
after treatment with vehicle or 8-CPT-cAMP (100 M). aP2 was blotted as a loading control, and data are representative of three experiments. C, induction of
hepatic Pgc-1 and NT-Pgc-1 mRNA and protein by fasting for 12 h in C57BL/6J mice. -Actin was blotted as a loading control. Data presented as mean  S.E.
are representative of three experiments. D, relative expression of Pgc-1 and NT-Pgc-1 mRNA expression in BAT, brain, kidney, and liver of C57BL/6J mice. Data
presented as mean  S.E. are representative of three experiments. E, relative expression levels of NT-PGC-1 protein in BAT, brain, kidney, and liver of control
(wild type (WT)) and PGC-1 null mice. KO, knock-out. F, induction of PGC-1 and NT-PGC-1 protein in brown adipose tissue by cold exposure (4 °C) for 5 h in
3-month-old male Zucker rats. BAT whole cell extracts for room temperature (100 g) and cold-exposed (30 g) rats were blotted for -actin as a loading
control, and data (mean  S.E.) are representative of three experiments. G, relative expression of NT-PGC-1 and PGC-1 protein in whole cell extracts (30 g)
of brains from 3-month-old male Zucker rats. NT-PGC-1 and PGC-1 overexpressed in COS cells were loaded as positive controls. H, NT-PGC-1 expression in
whole cell extracts (100 g) from human heart tissue provided by the National Disease Research Interchange. NT-PGC-1 and PGC-1 overexpressed in COS
cells were loaded as positive controls. I, relative targeting of NT-PGC-1 and PGC-1 to the proteosome. NT-PGC-1 and PGC-1 protein expression in CHO-K1
cells transduced with PGC-1 or NT-PGC-1 vectors for 24 h was followed by treatment with vehicle or proteosome inhibitor (1 M MG132) for 5 h. Data are
representative of three experiments.
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(Fig. 5A). These data show that NT-PGC-1 physically inter-
acts with both PPAR and PPAR but differs from PGC-1 in
that its interaction with both PPAR and PPAR shows greater
ligand dependence.
As a second approach to test for physical interaction between
NT-PGC-1 and nuclear receptors, 35S-PPAR and 35S-
PPAR were incubated with GST fusions of NT-PGC-1 or
PGC-1 in the absence or presence of ligands for each receptor.
Both receptors were pulled down with GST-NT-PGC-1 in a
ligand-dependent manner (Fig. 5B). GST-PGC-1 also pulled
down both nuclear receptors, and the addition of ligand pro-
duced a significant increase in that interaction (Fig. 5B). How-
ever, PGC-1 differed fromNT-PGC-1 in that the interaction
between GST-PGC-1 and 35S-PPAR was quite strong in the
absence of ligand andwas increased less than 2-fold by addition
of ligand (Fig. 5B). As a third approach to evaluate interaction of
NT-PGC-1 with PPAR in cells, the two proteins were co-
immunoprecipitated (co-IP) fromCOS cells in the absence and
presence of ligand. In Fig. 5C, upper panel, FLAG-tagged
PPAR was IP with anti-FLAG or nonspecific IgG, followed by
immunoblotting for NT-PGC-1 and PPAR in each pellet.
Essentially no PPAR or NT-PGC-1 was brought down by
nonspecific IgG (Fig. 5C). The amount of NT-PGC-1 co-IP
with PPAR increased 5-fold after treatment with receptor
ligand (Fig. 5C), whereas the amount of PPAR in each pellet
was similar. In the reverse configurationwith IP ofNT-PGC-1
and Western blotting of PPAR and NT-PGC-1, ligand
increased the amount of PPAR co-IP with NT-PGC-1 by
2-fold (Fig. 5C). Collectively, these data show first that NT-
PGC-1 interacts and can co-activate with PPAR receptors.
They also reveal subtle differences between NT-PGC-1 and
PGC-1 in that NT-PGC-1 shows greater ligand dependence
in its interactions with PPARs.
Transcriptional Activity of NT-PGC-1 in Brown Adipocytes—
To examine transcriptional activation of PGC-1 target genes
by NT-PGC-1, immortalized brown adipocytes were stably
transformed with lentiviral constructs expressing HA-tagged
NT-PGC-1, V5-epitope tagged PGC-1, or empty vector.
Selection pressure (blasticidin) was applied for 16 days, and
4–5 clones from each linewere screened to select lines express-
ing NT-PGC-1-HA and PGC-1-V5 (Fig. 6A) for further
study. Endogenous NT-PGC-1 was detected at 35–37 kDa
and comparably expressed in the empty vector (EV) and PGC-
1-V5 cell lines, whereas NT-PGC-1 was detected as a
doublet expressed at significantly higher levels in theNT-PGC-
1-HA-transformed lines (Fig. 6A). In the PGC-1-V5 trans-
formed lines, full-length PGC-1 was detected at 113 kDa and
at this exposure the protein was not visible in the EV or
NT-PGC-1-HA cell lines (Fig. 6A). In contrast, expression of
aP2 was similar among the lines, indicating that the cell lines
were comparably differentiated (Fig. 6A).
To examine the ability of NT-PGC-1 to increase transcrip-
tion of PGC-1 target genes, differentiated adipocytes derived
from the respective cell lines were treated with vehicle or a
mixture containing PPAR  retinoid X receptor  ligands or
PPAR  retinoid X receptor  ligands for 12 h, followed by
treatment with 8-CPT-cAMP for 6 h.Ucp1mRNA and protein
expression were low and comparable among all vehicle-treated
FIGURE 3. Regulation of subcellular distribution of NT-PGC-1 in CHO-K1
cells. A, representative confocal images of subcellular distribution of NT-PGC-
1-HA in CHO-K1 cells transduced with expression construct for NT-PGC-
1-HA for 24 h and treated with vehicle for 1 h prior to fixation and imaging.
The images on the left and right are presented with and without DAPI stain-
ing. B, representative confocal images showing subcellular distribution of
NT-PGC-1-HA in CHO-K1 cells transduced with expression construct for
NT-PGC-1-HA for 24 h and treated with 100 M 8-CPT-cAMP for 1 h prior to
fixation and imaging. The images on the left and right are presented with and
without DAPI staining. C, representative confocal images showing subcellular
distribution of NT-PGC-1-HA in CHO-K1 cells transduced with expression
construct for NT-PGC-1-HA for 24 h and treated with PKA inhibitor (H89) and
100 M 8-CPT-cAMP for 1 h prior to fixation and imaging. The images on the
left and right are presented with and without DAPI staining. D, representative
confocal images showing subcellular distribution of NT-PGC-1-HA in
CHO-K1 cells transduced with expression construct for NT-PGC-1-HA for
24 h and treated with p38 MAPK inhibitor (SB203580) and 100 M 8-CPT-
cAMP for 1 h prior to fixation and imaging. The images on the left and right are
presented with and without DAPI staining. E, image stacks from confocal
imaging of cells represented in A–D were analyzed using ImageJ software,
and the signal intensity from NT-PGC-1 co-localized with DAPI was
expressed relative to signal intensity in the whole cell. Means  S.E. are rep-
resentative of 80 –100 cells per treatment from three to four separate
experiments.
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lines, and treatment with either mixture induced Ucp1mRNA
and protein expression in all three lines (Fig. 6B). However, the
increase in Ucp1 mRNA in the NT-PGC-1 cell lines was
10-fold greater than the response in the empty vector line,
reaching 5.2  0.5 fmol of Ucp1 mRNA/g of RNA. These
levels are similar to levels seen in intact BAT (37) and are 2–4-
fold higher than the induction observed in the PGC-1-V5-
transformed cell line. This may be related in part to higher
expression of NT-PGC-1 versus PGC-1 in the respective cell
lines (Fig. 6A), even though one should keep in mind that only
10–20% of NT-PGC-1 protein is nuclear. UCP1 protein
expression paralleled Ucp1 mRNA in that it was nearly unde-
tectable in all three vehicle-treated lines. The ligand mixtures
increased UCP1 expression in all three lines, although the
increase with NT-PGC-1 was 3-fold higher than the com-
parable increase observed between the empty vector and PGC-
1-V5 lines (Fig. 6B).
In addition to the thermogenic target UCP1, we determined
the effect of PGC-1 and NT-PGC-1a on Cpt-1, which regu-
lates the entry of fatty acids into the mitochondria for oxida-
tion. In the absence of the ligand mixture, basal expression of
Cpt1 mRNA was 18-fold higher in the NT-PGC-1-HA line
versus the EV line (Fig. 6C). In contrast, basal expression of
Cpt1mRNAwas onlymodestly higher (2-fold) in PGC-1-V5
compared with the EV lines (Fig. 6C). The similar expression of
aP2 among the lines indicates that Cpt-1 mRNA expression
was compared at similar states of differentiation (Fig. 6C). The
induction of Cpt-1 by the ligand mixtures was similarly
enhanced by PGC-1 (3.9-fold) andNT-PGC-1 (4.1-fold) rel-
ative to EV, which differs from the significantly greater induc-
tion of Ucp1 by NT-PGC-1 relative to PGC-1 (see Fig. 6B).
Together, these data illustrate first that PGC-1 target genes
can be transcriptionally activated by NT-PGC-1 and second
that NT-PGC-1 and PGC-1 are likely to display differential
activity at different targets and/or contexts, with NT-PGC-1
preferentially enhancing expression of a subset of PGC-1 tar-
gets (e.g. basal expression of CPT1).
Cyclic AMP-dependent Recruitment of NT-PGC-1 to Tran-
scriptional Complexes Bound to Target Gene Promoters—The
ability of NT-PGC-1 to enhance expression of known PPAR/
PGC-1 target genes suggests that NT-PGC-1 is recruited to
theCpt1 andUcp1 promoters in a cAMP-dependent manner.
To assess NT-PGC-1 recruitment at these targets, we per-
formed chromatin immunoprecipitations from differentiated
brown adipocytes treated with vehicle or a ligand mixture con-
taining 8-CPT-cAMP,WY14693, and 9-cis-RA. The amount of
FIGURE 4. Regulation of subcellular distribution of NT-PGC-1 in undif-
ferentiated and differentiated brown adipocytes. A, representative con-
focal images showing subcellular distribution of NT-PGC-1-HA in undiffer-
entiated brown adipocytes stably transformed with NT-PGC-1-HA and
treated with vehicle for 1 h prior to fixation and imaging. The images on the
left and right are presented with and without DAPI staining. B, representative
confocal images showing subcellular distribution of NT-PGC-1-HA in undif-
ferentiated brown adipocytes stably transformed with NT-PGC-1-HA and
treated with 100 M 8-CPT-cAMP for 1 h prior to fixation and imaging. The
images on the left and right are presented with and without DAPI staining.
C, representative confocal images showing subcellular distribution of
NT-PGC-1-HA in fully differentiated brown adipocytes stably transformed
with NT-PGC-1-HA and treated with vehicle for 1 h prior to fixation and
imaging. The images on the left and right are presented with and without
DAPI staining. D, representative confocal images showing subcellular distri-
bution of NT-PGC-1-HA in fully differentiated brown adipocytes stably
transformed with NT-PGC-1-HA and treated with 100 M 8-CPT-cAMP for 1 h
prior to fixation and imaging. The images on the left and right are presented
with and without DAPI staining. E, image stacks from confocal imaging of all
cells represented in A–D were analyzed using ImageJ software, and the signal
intensity from NT-PGC-1 co-localized with DAPI was expressed relative to
signal intensity in the whole cell. Means  S.E. are representative of 50 – 60
cells per treatment from three to four separate experiments.
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NT-PGC-1-HA bound to Cpt1 and Ucp1 enhancers in
immunoprecipitated chromatin was measured by real time
PCR using primers (829 to 629) spanning the PPAR ele-
ment (762 to 744) in the Cpt1 promoter and primers
flanking the enhancer of theUcp1 promoter (38). No signal was
detected in negative controls consisting of chromatin immuno-
precipitated with control IgG or chromatin immunoprecipi-
tated from the EV cell line with HA IgG (Fig. 6,D and E). As an
additional negative control, we amplified an intragenic region
3 of the respective Cpt-1 and Ucp1 promoters in the immu-
noprecipitated chromatin and found no evidence that NT-
PGC-1-HA was bound to these regions of either gene (Fig. 6,
D and E). Nonimmunoprecipitated chromatin was amplified as
a positive control and to establish that equal amounts of chro-
matin from each sample were subjected to immunoprecipita-
tion. NT-PGC-1-HA was bound to the Cpt1 (Fig. 6D) and
Ucp1 enhancers (Fig. 6E) in the basal state, and binding was
increased 2–3-fold byPKAandnuclear receptor activation (Fig.
6, D and E). These findings show that conditions that stabilize
and increase nuclear content of NT-PGC-1 also activate
nuclear receptors, induce transcriptional activation of known
target genes (Cpt1 and Ucp1), and produce a concomitant
increase in recruitment of NT-PGC-1 to the respective pro-
moters of each gene. Collectively, these findings make the case
that NT-PGC-1 is a dynamically regulated, biologically active
form of PGC-1.
NT-PGC-1 Enhances Mitochondrial Biogenesis—The cen-
tral function of PGC-1 in many cellular contexts and in par-
ticular in brown adipocytes is to promote mitochondrial
biogenesis. To determine whether NT-PGC-1 retains this
function, we measured mitochondrial DNA copy number (by
assessing the ratio of mitochondrial to nuclear DNA) (32) in
differentiated brown adipocytes stably transformedwith empty
vector, NT-PGC-1-HA, or PGC-1-V5. Differentiated adipo-
cytes were also imagedwithMitofluor Red 589, and fluorescent
intensity was measured using fluorescence microscopy with
TRITC filters (excitation 484/15 and emission 555/25). In
NT-PGC-1-HA versus empty vector-transformed adipocytes,
the mtDNA/nuDNA ratio was 2.1  0.1-fold higher, and the
Mitofluor Red intensity was 1.86  0.03-fold higher (Fig. 7).
The PGC-1-V5-transformed line showed a similar increase in
mitochondrial number and mass (1.9  0.1-fold) compared
with the empty vector line with both methods (Fig. 7). These
data illustrate that NT-PGC-1 is capable of enhancing mito-
chondrial biogenesis in brown adipocytes and thereby retains in
its condensed sequence the major cellular function of full-
length PGC-1.
DISCUSSION
Alternative splicing expands the translational repertoire of
numerous genes by producing multiple transcripts that encode
FIGURE 5. Physical and functional interaction of NT-PGC-1-HA with
PPAR and PPAR. A, ligand-dependent transactivation of Gal4-PPAR and
Gal4-PPAR by PGC-1 and NT-PGC-1 in Chinese hamster ovary cells tran-
siently transfected with GAL4-responsive luciferase reporter gene (pGK) and
a pRL-SV40 plasmid expressing Renilla luciferase for normalization. Luciferase
activity was measured 24 h after treatment with vehicle (DMSO), 10 M
WY14693, or 10 M BRL49653. Fold changes in luciferase activity were
expressed relative to cells transfected with pGK alone. Data represent
means  S.E. from three experiments. B, ligand-dependent interaction of
35S-PPAR or 35S-PPAR by GST-tagged PGC-1 and NT-PGC-1. The 35S-
labeled nuclear receptors were produced by TNT T7 in vitro translation system
and incubated with GST-tagged PGC-1 or NT-PGC-1 for 1 h in the absence
and presence of ligands for the respective receptors. Autoradiograms are
representative of three experiments. C, co-immunoprecipitation analysis of
protein-protein interaction of HA-tagged NT-PGC-1 with FLAG-tagged
PPAR in COS cells. 24 h after treatment with vehicle (DMSO) or 10 M
WY14693, whole cell extracts were immunoprecipitated with anti-FLAG (top
panel), anti-HA (bottom panel), mouse preimmune IgG (top panel), or rabbit
IgG (bottom panel). Using Western blots (WB), the respective immunoprecipi-
tates were sequentially probed with anti-HA and anti-FLAG (top panel) or
anti-FLAG and anti-HA (bottom panel) to test for co-IP of NT-PGC-1 and
PPAR and IP efficiency. Blots are representative of four experiments.
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different protein sequences, and most transcribed genes con-
tain sequences that can be alternatively spliced (26). Tile-based
microarrays andmassive parallel sequencing have been used to
interrogate the transcriptional complexity among tissues (39)
and in cells during different growth phases and conditions (40).
The studies show reproducible patterns of alternative splicing
that are tissue- and cell type-specific, regulated during prolifer-
ation and differentiation, and responsive to post-translational
inputs. Thus, regulated splicing of the transcriptome may be
deterministic with respect to cell identity and function. The
degree to which transcriptional complexity is actually trans-
lated is uncertain, given that 30% of alternativemRNA isoforms
contain premature termination codons (41, 42). Premature ter-
mination codons are predicted to target these transcripts for
rapid decay by nonsense-mediated RNA decay (43, 44), a sur-
veillance system that preemptively rids the cell of truncated
versions of proteins with potentially deleterious dominant neg-
ative or gain of function activity (43, 44). Accordingly, to pro-
FIGURE 6. Induction of Ucp1 mRNA and protein expression in immortalized brown adipocytes stably transformed with empty vector, HA-tagged
NT-PGC-1, or V5-tagged PGC-1. A, Western blot analysis of NT-PGC-1-HA and PGC-1-V5 protein expression in brown adipocytes expressing HA-tagged
NT-PGC-1, V5-tagged PGC-1, or empty vector. IB, immunoblot. Upper panel shows detection of respective proteins with anti-HA or anti-V5, and lower panel
shows detection of both proteins in representative clones using an antibody raised against the N-terminal region of PGC-1. B, real time PCR and Western blot
analysis of ligand-dependent induction of Ucp1 mRNA and protein in differentiated brown adipocytes expressing HA-tagged NT-PGC-1, V5-tagged PGC-1,
or empty vector. Replicate wells of each line were treated with ligand mixtures containing 1 M 9-cis-RA and either 10 M WY14693 or BRL49653 for 12 h,
followed by 6 h with 100 M 8-CPT-cAMP. Cell extracts were blotted for UCP1. aP2 was blotted as a differentiation and loading control. Data represent mean 
S.E. of three experiments. C, real time PCR analysis of basal expression of Cpt-1 mRNA expression in differentiated brown adipocytes expressing HA-tagged
NT-PGC-1, V5-tagged PGC-1, or empty vector. Cell extracts from replicate cultures were blotted for aP2 as a differentiation and loading control. Data
represent mean  S.E. of three experiments. D, recruitment of NT-PGC-1-HA to Cpt-1 promoter in differentiated brown adipocytes. Differentiated brown
adipocytes expressing empty vector or NT-PGC-1-HA were treated for 12 h with vehicle or 100 M 8-CPT-cAMP, and cross-linked chromatin was immuno-
precipitated with either anti-HA or mouse preimmune IgG. The amount of the Cpt-1 enhancer (top panel) or an intragenic region 3 of the enhancer (bottom
panel) co-immunoprecipitated with NT-PGC-1 was measured by real time PCR using 4 ODs of immunoprecipitated chromatin. Agarose gel showing speci-
ficity of PCR and data are representative of three similar experiments. E, recruitment of NT-PGC-1-HA to UCP-1 promoter in differentiated brown adipocytes.
Differentiated brown adipocytes expressing NT-PGC-1-HA were treated for 12 h with vehicle or 100 M 8-CPT-cAMP, and cross-linked chromatin was
immunoprecipitated with either anti-HA or mouse preimmune IgG. The amount of the UCP-1 enhancer co-immunoprecipitated with NT-PGC-1 (top panel) or
an intragenic region 3 of the enhancer (bottom panel) was measured by real time PCR using 4 ODs of immunoprecipitated chromatin. Agarose gel showing
specificity of PCR and data are representative of three similar experiments.
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pose a function for a newly recognized, alternatively spliced
species, it is imperative to determine that it leads to a protein
expressed in vivo at meaningful levels. Our findings clearly
show that the NT-Pgc-1 transcript is present at levels compa-
rable with the transcript for full-length Pgc-1 (suggesting that
NT-Pgc-1 mRNA is not eliminated by the nonsense-mediated
RNA decay system) and leads to readily detectable levels of
NT-PGC-1 protein in several tissues from mice, rats, and
humans. Not only is NT-Pgc-1 mRNA not eliminated, it can
become the predominant splicing isoform in some tissues.
More importantly, in essentially all tissues from all species so
far examined, expression of NT-Pgc-1 is significantly higher
than Pgc-1 except under conditions where both proteins are
highly induced (i.e. fasting and cold exposure). Perhaps more
importantly, the complete conservation of the intronic
sequence spanning the two alternative 3 splice sites across all
species so far examined strongly supports an important role for
NT-PGC-1 in the biology of PGC-1.
This work shows that the physiological inputs that in-
crease Pgc-1 and NT-Pgc-1 mRNA produce a correspond-
ing increase in expression of the two proteins. Regulated
expression of endogenous PGC-1 protein is often difficult
to detect due to its relatively short half-life (13) and also due
to numerous post-translational modifications that may
modify antibody recognition of epitopes in affected se-
quences (11–13, 20, 24, 34, 45). Measurement of PGC-1 and
NT-PGC-1 expression in this study was accomplished using
two antibodies recognizing epitopes spanning the N-terminal
transactivation domain of PGC-1, a region common to the
two isoforms where post-translational modification has not
been reported. The predictedmolecularmass ofNT-PGC-1 is
30 kDa, but both in vitro translated and overexpressed NT-
PGC-1 are detected at 35–38 kDa. This is similar to the
difference between predicted (92 kDa) and observed (113 kDa)
molecular mass of PGC-1 (1). Expression of endogenous
PGC-1 and NT-PGC-1 was increased in BAT by short term
cold exposure and in immortalized brown adipocytes after
treatment with a cell-permeable cAMP analog. Induction of
PGC-1 and NT-PGC-1 was also detected after an overnight
fast in liver nuclear extracts. Brain was the site of highest NT-
Pgc-1 expression among the tissues surveyed, and it was also
the site where splicing appeared to favor formation of
NT-Pgc-1 mRNA over PGC-1. We found no evidence that
cold exposure or fasting altered NT-Pgc-1 expression in the
whole brain, and the signals or physiological states that regulate
its expression in this site remain unclear. In addition to differ-
ences in relative expression levels ofNT-Pgc-1 among tissues,
we observed subtle differences in apparent molecular mass.
The basis for this is unclear, although tissue-specific differences
in alternative promoter/first exon usage and the type or extent
of post-translational modifications could be involved.
In tissues studied to date, basal expression of NT-PGC-1
protein is consistently higher than full-length PGC-1 despite
similar or lower levels of mRNAs. We hypothesized that the
splice variant may be more stable based on the absence of the
secondCdc4 phosphodegron (aa 293–300) (14) andC-terminal
arginine/serine-rich domains involved in targeting PGC-1 for
ubiquitination and degradation (25). Our findings that short
term proteosome inhibition produced onlymodest increases in
NT-PGC-1 (2-fold) compared with dramatic increases in
PGC-1 (10–11-fold) are consistent with this prediction.
Based on its size, it is surprising thatNT-PGC-1 is primarily
cytosolic in untreated cells and equilibrated across the nuclear
membrane only after activation of PKA. One possibility is that
NT-PGC-1 is bound to cytosolic proteins that affect its ability
to diffuse into the nucleus. Although activation of PKA allows
NT-PGC-1 to equilibrate across the nuclear membrane, it is
unclear whether NT-PGC-1 is actually a substrate of PKA. At
least part of the response can be attributed to PKA-dependent
activation of p38 MAPK, which phosphorylates PGC-1 (13,
46); however, the major proportion of the response is retained
after inhibition of p38MAPK (Fig. 3,D and E). In contrast, PKA
inhibition completely blocked cAMP-dependent redistribution
of NT-PGC-1 to the nucleus and actually lowered nuclear
content to a level below that seen in vehicle-treated cells. These
findings indicate that PKA provides input to regulating NT-
PGC-1 distribution within the cell over the full range of its
activation state. To understand this response, it will be impor-
tant to determine whether PKA is regulating the interaction
between NT-PGC-1 and a protein(s) that alters its ability to
equilibrate across the nuclear membrane.
Despite the fact that only 10–20% of exogenously expressed
NT-PGC-1 protein is nuclear, we provide unambiguous data
that NT-PGC-1 physically interacts with and transactivates
nuclear receptors in a ligand-dependent manner, suggesting
that nuclearNT-PGC-1 is active. The conditions that increase
nuclear content of NT-PGC-1 (i.e. PKA activation) also
increase transcriptional activity of PPAR, PPAR, and recruit-
ment of NT-PGC-1 to associated transcriptional complexes.
However, it should be noted that under these conditions, a sig-
nificant amount of total cellular NT-PGC-1 is retained in the
cytoplasm. The implications of this unique property of NT-
PGC-1 could be related to recent work showing that C-termi-
nal domains in PGC-1 that are not present in NT-PGC-1
FIGURE 7. NT-PGC-1 enhances mitochondrial biogenesis in differenti-
ated brown adipocytes. Real time PCR analysis of the ratio of mitochondria
to nuclear DNA and Mitofluor Red fluorescence intensity in differentiated
brown adipocytes expressing HA-tagged NT-PGC-1, V5-tagged PGC-1, or
empty vector is shown. Data represent mean  S.E. of three experiments with
3–10 replicates per experiment.
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target nuclear PGC-1 for polyubiquitination and proteosomal
degradation (25). One interpretation is that regulation of
PGC-1 activity is accomplished by somewhat different means
for the two PGC-1 isoforms. For example, full-length PGC-1
activity may be predominantly regulated by ubiquitination and
degradation and NT-PGC-1 activity by nuclear/cytoplasmic
relocalization. Distinct regulatory mechanisms may increase
adaptability in responses to specific signals (e.g. to signals that
activate a specific protein isoform) and strengthen or extend
the duration of responses (e.g. to signals that activate both pro-
teins). Clearly, it will be important to understand how the
responses of the PGC-1 isoforms are integrated in tissues
where both are expressed.
Despite the fact that NT-PGC-1 lacks C-terminal domains
proposed to be important for transcriptional activation of
endogenous genes (21, 22), we show thatNT-PGC-1 leads to a
profound enhancement of Ucp1 and Cpt-1 expression in sta-
bly transformed brown adipocytes (Fig. 6). In the same cells,
NT-PGC-1, as well as PGC-1, also led to increased expres-
sion of other known PGC-1 target genes (e.g. Tfam,Mcad,Cyt
c1, and CoxII) and produced a comparable 2-fold increase in
mitochondrial density. A limitation of these studies is that
endogenous NT-PGC-1 and PGC-1 are present in the con-
trol (empty vector), NT-PGC-1, and PGC-1 transformed
lines so we cannot rule out some contribution of the endoge-
nous proteins to the phenotype of the cells. However, our com-
parison of protein expression indicates that endogenous
PGC-1 is quite low (Fig. 6A). The enhancement of Ucp1 and
Cpt-1 expression by NT-PGC-1 was paralleled by clear data
showing that NT-PGC-1 coordinates the assembly of tran-
scriptional complexes whose binding to the Ucp1 and Cpt-1
promoters is enhanced by cAMP (Fig. 6, D and E). Although
expression of both genes and binding of NT-PGC-1 to the
respective promoters was enhanced by cAMP and ligands, a
clear distinction in the role of ligands in transactivating each
gene was evident among the cell lines. In particular, the basal
expression of Ucp1 mRNA and protein was comparable
between the NT-PGC-1 and empty vector cell lines, whereas
Cpt-1mRNAwas15–20-fold higher in theNT-PGC-1 line
compared with the empty vector or PGC-1 lines. In contrast,
the induction ofUcp1mRNA by the cAMP ligand mixture was
10-fold higher in the NT-PGC-1 line, and the induction of
Cpt-1 mRNA by ligands was comparable between the lines.
Although the underlying reasons are unclear, these findings
support the idea that NT-PGC-1 and PGC-1 are differen-
tially active in different contexts, with Cpt-1 in the absence of
cAMP and PPAR ligands representing a target that is uniquely
sensitive to NT-PGC-1.
Strategies for evaluating the in vivo functions of NT-PGC-1
in the absence of PGC-1 are technically challenging due to the
difficulty of selectively disrupting expression of the full-length
PGC-1 transcript. However, comparison of PGC-1 nullmice
produced by different gene targeting strategies (15, 16) reveals
some differences that may relate to the function of NT-PGC-
1. PGC-1nullmice produced by Lin et al. (15) lack exons 3–5
(which encode the NR interaction domains) and lead to a
frameshift in the remaining exons, consistent with a compete
lack of PGC-1 activity. PGC-1 null mice produced by Leone
et al. c retain exons 1- 5, which, as noted by the authors, may
permit the expression of a truncated form (aa 1–254) of PGC-
1. This protein would be only 16 aa shorter than NT-PGC-1
and would include all major motifs and domains of NT-
PGC-1 except for the p38 phosphorylation sites (aa 262 and
268), which could of course be important for regulation of a
truncated protein (see Fig. 1C). The mice of Lin et al. (15) dis-
play a more severe phenotype with early postnatal mortality
(50%) and profound hyperactivity, and the mice of Leone et al.
(16) showed no increase in mortality and reduced locomotor
activity. Moreover, the induction of Ucp1mRNA in BAT after
5 h of cold exposure was severely compromised in the Lin et al.
(15) mice but uncompromised in the Leone et al. (16) mice.
Based on the biological activity of NT-PGC-1 described here,
it seems likely that a 1–254-aa form of PGC-1 could be
responsible for the phenotypic differences between the two
mouse lines. It will be important in future experiments to test
for expression and abundance of this form of PGC-1 in the
mouse line described by Leone et al. (16).
The data presented here provide a compelling case that NT-
PGC-1 is an abundant, previously unrecognized form of
PGC-1 that is produced by alternative splicing between exons
6 and 7. Expression of NT-PGC-1 in BAT and liver is dynam-
ically regulated in the context of the physiological signals that
regulate full-length PGC-1. NT-PGC-1 is also expressed in
other tissues where PGC-1 plays important roles in regulation
of cell function and energymetabolismand is particularly abun-
dant in the central nervous system, where PGC-1 has a neu-
roprotective function (10, 15). The truncated domain structure
of NT-PGC-1 conveys unique properties with respect to sub-
cellular localization, protein stability, transcription factor
interaction, and target gene activation. We propose that the
unique properties of NT-PGC-1 enable it to produce a cell
context-specific subset of responses that complement, overlap,
or prolong the actions of PGC-1. As such, it represents a novel
component and an additional level of complexity within the
signaling network thatmediates adaptive responses inmetabol-
ically active tissues.
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Mootha, V. K., Jäger, S., Vianna, C. R., Reznick, R.M., Cui, L., Manieri, M.,
Donovan, M. X., Wu, Z., Cooper, M. P., Fan, M. C., Rohas, L. M., Zavacki,
A. M., Cinti, S., Shulman, G. I., Lowell, B. B., Krainc, D., and Spiegelman,
B. M. (2004) Cell 119, 121–135
16. Leone, T. C., Lehman, J. J., Finck, B. N., Schaeffer, P. J., Wende, A. R.,
Boudina, S., Courtois, M., Wozniak, D. F., Sambandam, N., Bernal-
Mizrachi, C., Chen, Z., Holloszy, J. O., Medeiros, D. M., Schmidt, R. E.,
Saffitz, J. E., Abel, E. D., Semenkovich, C. F., and Kelly, D. P. (2005) PLOS
Biol. 3, e101–e115
17. Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O’Malley, B., and
Spiegelman, B. M. (1999) Science 286, 1368–1371
18. Puigserver, P., and Spiegelman, B. M. (2003) Endocr. Rev. 24, 78–90
19. Oberkofler, H., Esterbauer, H., Linnemayr, V., Strosberg, A. D., Krempler,
F., and Patsch, W. (2002) J. Biol. Chem. 277, 16750–16757
20. Knutti, D., Kressler, D., and Kralli, A. (2001) Proc. Natl. Acad. Sci. U.S.A.
98, 9713–9718
21. Wallberg, A. E., Yamamura, S., Malik, S., Spiegelman, B. M., and Roeder,
R. G. (2003)Mol. Cell 12, 1137–1149
22. Monsalve, M., Wu, Z., Adelmant, G., Puigserver, P., Fan, M., and
Spiegelman, B. M. (2000)Mol. Cell 6, 307–316
23. Li, X., Monks, B., Ge, Q., and Birnbaum, M. J. (2007) Nature 447,
1012–1016
24. Teyssier, C., Ma, H., Emter, R., Kralli, A., and Stallcup, M. R. (2005)Genes
Dev. 19, 1466–1473
25. Sano, M., Tokudome, S., Shimizu, N., Yoshikawa, N., Ogawa, C.,
Shirakawa, K., Endo, J., Katayama, T., Yuasa, S., Ieda, M., Makino, S.,
Hattori, F., Tanaka, H., and Fukuda, K. (2007) J. Biol. Chem. 282,
25970–25980
26. Johnson, J. M., Castle, J., Garrett-Engele, P., Kan, Z., Loerch, P. M., Arm-
our, C. D., Santos, R., Schadt, E. E., Stoughton, R., and Shoemaker, D. D.
(2003) Science 302, 2141–2144
27. Commins, S. P., Watson, P. M., Padgett, M. A., Dudley, A., Argyropoulos,
G., and Gettys, T. W. (1999) Endocrinology 140, 292–300
28. Klein, J., Fasshauer, M., Ito, M., Lowell, B. B., Benito, M., and Kahn, C. R.
(1999) J. Biol. Chem. 274, 34795–34802
29. Fasshauer,M., Klein, J., Kriauciunas, K.M., Ueki, K., Benito,M., andKahn,
C. R. (2001)Mol. Cell. Biol. 21, 319–329
30. Adamson, A. W., Suchankova, G., Rufo, C., Nakamura, M. T., Teran-
Garcia, M., Clarke, S. D., and Gettys, T. W. (2006) Biochem. J. 399,
285–295
31. Gerhart-Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S. H., Mosto-
slavsky, R., Alt, F. W., Wu, Z., and Puigserver, P. (2007) EMBO J. 26,
1913–1923
32. Bogacka, I., Xie, H., Bray, G. A., and Smith, S. R. (2005) Diabetes 54,
1392–1399
33. Michael, L. F., Wu, Z., Cheatham, R. B., Puigserver, P., Adelmant, G.,
Lehman, J. J., Kelly, D. P., and Spiegelman, B. M. (2001) Proc. Natl. Acad.
Sci. U.S.A. 98, 3820–3825
34. Nemoto, S., Fergusson, M. M., and Finkel, T. (2005) J. Biol. Chem. 280,
16456–16460
35. Miura, S., Kai, Y., Kamei, Y., and Ezaki, O. (2008) Endocrinology 149,
4527–4533
36. Cyert, M. S. (2001) J. Biol. Chem. 276, 20805–20808
37. Zhang, Y., Kilroy, G., Henagan, T., Prpic-Uhing, V., Richards, W. G., Ban-
non, A. W., Mynatt, R. L., and Gettys, T. W. (2005) FASEB J. 19,
1482–1491
38. Rim, J. S., and Kozak, L. P. (2002) J. Biol. Chem. 277, 34589–34600
39. Grosso, A. R., Gomes, A. Q., Barbosa-Morais, N. L., Caldeira, S., Thorne,
N. P., Grech, G., von Lindern, M., and Carmo-Fonseca, M. (2008)Nucleic
Acids Res. 36, 4823–4832
40. Wilhelm, B. T., Marguerat, S., Watt, S., Schubert, F., Wood, V., Good-
head, I., Penkett, C. J., Rogers, J., and Bähler, J. (2008) Nature 453,
1239–1243
41. Green, R. E., Lewis, B. P., Hillman, R. T., Blanchette, M., Lareau, L. F.,
Garnett, A. T., Rio, D. C., and Brenner, S. E. (2003) Bioinformatics 19,
i118–i121
42. Lewis, B. P., Green, R. E., and Brenner, S. E. (2003) Proc. Natl. Acad. Sci.
U.S.A. 100, 189–192
43. Nagy, E., and Maquat, L. E. (1998) Trends Biochem. Sci. 23, 198–199
44. Chang, Y. F., Imam, J. S., andWilkinson,M. F. (2007)Annu. Rev. Biochem.
76, 51–74
45. Housley, M. P., Udeshi, N. D., Rodgers, J. T., Shabanowitz, J., Puigserver,
P., Hunt, D. F., and Hart, G. W. (2009) J. Biol. Chem. 284, 5148–5157
46. Cao, W., Daniel, K. W., Robidoux, J., Puigserver, P., Medvedev, A. V., Bai,
X., Floering, L.M., Spiegelman, B.M., andCollins, S. (2004)Mol. Cell. Biol.
24, 3057–3067
mRNA Splicing Produces an Active Short Isoform of PGC-1
32826 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 47 • NOVEMBER 20, 2009
